Fulcrum Therapeutics annual cash and equivalents
2018
2019
2020
2021
2022
2023
2024
2025
Fulcrum Therapeutics Cash & Equivalents Growth & History (FULC)
Fulcrum Therapeutics's cash and equivalents was $197.5M for fiscal 2025.
View full Fulcrum Therapeutics company overviewFulcrum Therapeutics annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $197.5M | $139.3M | +239.33% |
| 2024 | 2024-12-31 | $58.2M | $32.6M | +127.72% |
| 2023 | 2023-12-31 | $25.6M | −$9.5M | −27.17% |
| 2022 | 2022-12-31 | $35.1M | −$314,000 | −0.89% |
| 2021 | 2021-12-31 | $35.4M | −$21.6M | −37.93% |
| 2020 | 2020-12-31 | $57.1M | −$39.7M | −41.01% |
| 2019 | 2019-12-31 | $96.7M | $23.9M | +32.85% |
| 2018 | 2018-12-31 | $72.8M | — | — |
Fulcrum Therapeutics quarterly cash and equivalents
Q4.18
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $48.5M | $5.9M | +13.80% |
| Q1 2026 | 2026-03-31 | $50.3M | $8.1M | +19.16% |
| Q4 2025 | 2025-12-31 | $197.5M | $139.3M | +239.33% |
| Q3 2025 | 2025-09-30 | $47.1M | −$25.6M | −35.18% |
| Q2 2025 | 2025-06-30 | $42.6M | −$44.1M | −50.88% |
| Q1 2025 | 2025-03-31 | $42.2M | $2.2M | +5.58% |
| Q4 2024 | 2024-12-31 | $58.2M | $32.6M | +127.72% |
| Q3 2024 | 2024-09-30 | $72.6M | $42.5M | +141.46% |
| Q2 2024 | 2024-06-30 | $86.7M | $52.7M | +155.26% |
| Q1 2024 | 2024-03-31 | $39.9M | $5.2M | +15.01% |
| Q4 2023 | 2023-12-31 | $25.6M | −$9.5M | −27.17% |
| Q3 2023 | 2023-09-30 | $30.1M | −$60.9M | −66.92% |
| Q2 2023 | 2023-06-30 | $34.0M | −$6.2M | −15.41% |
| Q1 2023 | 2023-03-31 | $34.7M | $1.4M | +4.27% |
| Q4 2022 | 2022-12-31 | $35.1M | −$314,000 | −0.89% |
| Q3 2022 | 2022-09-30 | $90.9M | $25.5M | +38.89% |
| Q2 2022 | 2022-06-30 | $40.2M | −$16.6M | −29.28% |
| Q1 2022 | 2022-03-31 | $33.3M | −$67.4M | −66.93% |
| Q4 2021 | 2021-12-31 | $35.4M | −$21.6M | −37.93% |
| Q3 2021 | 2021-09-30 | $65.5M | −$19.7M | −23.17% |
| Q2 2021 | 2021-06-30 | $56.8M | −$18.9M | −25.01% |
| Q1 2021 | 2021-03-31 | $100.7M | $75.4M | +296.96% |
| Q4 2020 | 2020-12-31 | $57.1M | −$39.7M | −41.01% |
| Q3 2020 | 2020-09-30 | $85.2M | −$16.4M | −16.12% |
| Q2 2020 | 2020-06-30 | $75.7M | $26.1M | +52.57% |
| Q1 2020 | 2020-03-31 | $25.4M | — | — |
| Q4 2019 | 2019-12-31 | $96.7M | $23.9M | +32.85% |
| Q3 2019 | 2019-09-30 | $101.6M | — | — |
| Q2 2019 | 2019-06-30 | $49.6M | — | — |
| Q4 2018 | 2018-12-31 | $72.8M | — | — |
Fulcrum Therapeutics cash and equivalents trends
Over the last five fiscal years, Fulcrum Therapeutics's cash and equivalents increased from $57.1M to $197.5M, a change of $140.5M. The latest reported quarter, Q2 2026, shows $48.5M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fulcrum Therapeutics source filings ↗